Astrazeneca revenue surges amid Chinese import tax allegations
Astrazeneca’s revenue jumped 21 per cent last year despite growing troubles over its presence in China. The pharmaceutical ...
ジャパンタイムズ7d
AstraZeneca and Daiichi’s breast cancer drug gets EU backing
The green light from the European Medicines Agency is the first backing in the EU for the medicine, following its approval in ...
AstraZeneca shares rise as China probe update reassures
AstraZeneca shares rose on Thursday after the drugmaker said it could face a fine of up to $4.5 million in China over ...
AstraZeneca: CHMP Recommends Approval Of Imfinzi In The EU
AstraZeneca (AZN.L, AZN) announced Imfinzi was recommended for approval in the European Union by CHMP as first and only immunotherapy ...
AstraZeneca Stock Rally Will be Tested by Answers on China Probe
A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...
foxbangor1d
Global stocks rise on easing trade fears, company earnings
Stock markets rose Thursday on easing trade tensions and thanks to some strong company earnings, analysts said.
AstraZeneca's Imfinzi endorsed for EU approval for lung cancer care
(Alliance News) - AstraZeneca PLC on Monday said Imfinzi has been recommended for approval in the EU as monotherapy for limited-stage small cell lung cancer.
EuropaWire3d
AstraZeneca’s Imfinzi Recommended for EU Approval as Breakthrough Treatment for Limited-Stage Small Cell Lung Cancer
AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...